NCT00889655

Brief Summary

Prior to colonoscopies, the colon is cleansed using a laxative. Golytely is approved by the FDA for this purpose. Another laxative, called MiraLax, is approved by the FDA to relieve constipation, but it is not approved specifically for preparation for a colonoscopy. Nonetheless, it is commonly used in clinical practice for this purpose, just as is Golytely. The purpose of this study is to compare Golytely and MiraLax in two ways: to see whether one is better tolerated by patients than the other and to see whether one more effectively cleanses the bowel than the other. The investigators' hypothesis is that these 2 bowel preparation methods are equally effective in bowel cleansing, but that patients prefer Miralax to Golytely.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
432

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2009

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 29, 2009

Completed
2 days until next milestone

Study Start

First participant enrolled

May 1, 2009

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

April 29, 2009

Status Verified

April 1, 2009

Enrollment Period

1 year

First QC Date

April 28, 2009

Last Update Submit

April 28, 2009

Conditions

Keywords

efficacy of bowel cleansingpatient tolerabilityGolytelyMiraLaxcolonoscopy preparationbowel preparationscreening colonoscopy

Outcome Measures

Primary Outcomes (1)

  • bowel cleanliness as rated by the boston bowel prep survey

    measured at the time of colonoscopy

Secondary Outcomes (1)

  • patient tolerability

    measured at check in to colonoscopy

Study Arms (2)

Golytely

ACTIVE COMPARATOR

216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy

Drug: Golytely (polyethylene glycol)

MiraLax

EXPERIMENTAL

216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser

Drug: MiraLax (polyethylene glycol 3350)

Interventions

4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.

Golytely

238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.

MiraLax

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • average risk screening for colon cancer

You may not qualify if:

  • subjects with a history of constipation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oregon Health & Sciences University

Portland, Oregon, 97239, United States

Location

Related Publications (1)

  • Enestvedt BK, Fennerty MB, Eisen GM. Randomised clinical trial: MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability in bowel preparation for colonoscopy. Aliment Pharmacol Ther. 2011 Jan;33(1):33-40. doi: 10.1111/j.1365-2036.2010.04493.x. Epub 2010 Oct 25.

MeSH Terms

Interventions

GolytelyPolyethylene Glycolspolyethylene glycol 3350

Intervention Hierarchy (Ancestors)

Ethylene GlycolsGlycolsAlcoholsOrganic ChemicalsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and Agriculture

Central Study Contacts

Glenn Eisen, MD, MPH

CONTACT

Brintha K Enestvedt, MD, MBA

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 28, 2009

First Posted

April 29, 2009

Study Start

May 1, 2009

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

April 29, 2009

Record last verified: 2009-04

Locations